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Interleukin-1beta causes acute lung injury via alphavbeta5 and
alphavbeta6 integrin-dependent mechanisms
Abstract
Interleukin (IL)-1beta has previously been shown to be among the most biologically active cytokines in
the lungs of patients with acute lung injury (ALI). Furthermore, there is experimental evidence that lung
vascular permeability increases after short-term exposure to IL-1 protein, although the exact mechanism
is unknown. Therefore, the objective of this study was to determine the mechanisms of
IL-1beta-mediated increase in lung vascular permeability and pulmonary edema following transient
overexpression of this cytokine in the lungs by adenoviral gene transfer. Lung vascular permeability
increased with intrapulmonary IL-1beta production with a maximal effect 7 days after instillation of the
adenovirus. Furthermore, inhibition of the alphavbeta6 integrin and/or transforming growth factor-beta
attenuated the IL-1beta-induced ALI. The results of in vitro studies indicated that IL-1beta caused the
activation of transforming growth factor-beta via RhoA/alphavbeta6 integrin-dependent mechanisms
and the inhibition of the alphavbeta6 integrin and/or transforming growth factor-beta signaling
completely blocked the IL-1beta-mediated protein permeability across alveolar epithelial cell
monolayers. In addition, IL-1beta increased protein permeability across lung endothelial cell
monolayers via RhoA- and alphavbeta5 integrin-dependent mechanisms. The final series of in vivo
experiments demonstrated that pretreatment with blocking antibodies to both the alphavbeta5 and
alphavbeta6 integrins had an additive protective effect against IL-1beta-induced ALI. In summary, these
results demonstrate a critical role for the alphavbeta5/beta6 integrins in mediating the IL-1beta-induced
ALI and indicate that these integrins could be a potentially attractive therapeutic target in ALI.
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ABSTRACT 
IL-1β has previously been shown to be one of the most biologically active cytokines in the 
lungs of patients with acute lung injury (ALI). Furthermore, there is experimental evidence that 
lung vascular permeability increases after short-term exposure to IL-1 protein, although the exact 
mechanism is unknown. Therefore, the objective of this study was to determine the mechanisms 
of IL-1β mediated increase in lung vascular permeability and pulmonary edema following 
transient overexpression of this cytokine in the lungs by adenoviral gene transfer. Lung vascular 
permeability increased with intrapulmonary IL-1β production with a maximal effect 7 days after 
instillation of the adenovirus. Furthermore, inhibition of the αvβ6 integrin and/or TGF-β 
attenuated the IL-1β-induced ALI. The results of in vitro studies indicated that IL-1β caused the 
activation of TGF-β via RhoA/αvβ6 integrin-dependent mechanisms and the inhibition of the 
αvβ6 integrin and/or TGF-β signaling completely blocked the IL-1β mediated protein 
permeability across alveolar epithelial cell monolayers. In addition, IL-1β increased protein 
permeability across lung endothelial cell monolayers via RhoA- and αvβ5 integrin-dependent 
mechanisms. The final series of in vivo experiments demonstrated that pretreatment with blocking 
antibodies to both the αvβ5 and αvβ6 integrins had an additive protective effect against IL-1β-
induced ALI. In summary, these results demonstrate a critical role for the αvβ5/β6 integrins in 
mediating the IL-1β induced acute lung injury and indicate that these integrins could be a 
potentially attractive therapeutic target in ALI.  
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INTRODUCTION 
Acute lung injury (ALI) is a devastating clinical syndrome in critically ill patients with an 
overall mortality rate of 30-40 percent.1 The syndrome is characterized by alveolar epithelial and 
lung endothelial injury leading to increased permeability across the alveolar-capillary barrier, 
pulmonary edema and acute respiratory failure.2 Despite an improved understanding of the 
pathogenesis of ALI in recent years, the molecular steps regulating the development of increased 
lung endothelial and epithelial permeability remain poorly understood and no specific 
pharmacological therapies are currently available. 
During the early phase of ALI, a variety of inflammatory mediators are released into the distal 
air spaces.2 Among those, IL-1β has been shown to be one of the most biologically active 
cytokines in the lungs early after the onset of ALI.3-5 Furthermore, IL-1β stimulates the 
production of a variety of chemokines (e.g. interleukin-8 [IL-8], monocyte chemotactic protein-1 
[MCP-1] and macrophage inflammatory protein-1α [MIP-1α]),6 involved in epithelial wound 
repair7, 8 and is a potent inducer of lung fibrosis.9, 10 It has been previously shown in rats that lung 
vascular permeability increases after short term exposure of IL-1α and IL-1β protein when given 
intratracheally.11, 12 However, the exact mechanism by which IL-1β causes the increased lung 
vascular permeability is unknown.  
Therefore, the objective of this study was to determine the mechanisms of IL-1β mediated 
increase in lung vascular permeability and pulmonary edema following transient overexpression 
of this cytokine in the lungs by adenoviral gene transfer. Our results demonstrate a critical role 
for the αvβ5/β6 integrins in mediating the IL-1β induced acute lung injury and indicate that these 
integrins could be a potentially attractive therapeutic target in ALI. 
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 MATERIALS AND METHODS 
Reagents and antibodies (Ab), recombinant adenovirus expressing human IL-1β (Ad-hIL-1β) 
and its control vector (Ad-Empty), details on the animal studies (Animals, Experimental protocol, 
Measurement of lung endothelial permeability to protein and pulmonary edema, Bronchoalveolar 
lavage (BAL) fluid and cell count, Measurement of IL-1β) and in vitro studies (Cell culture, 
Measurement of transepithelial and transendothelial albumin fluxes, Bioassay for TGFβ 
activation, RhoA activation assay, Western blot analysis for detecting phospho-Smad2, 
Immunocytochemistry for visualization of actin stress fibers, Immunoprecipitation for detecting 
phospho-β-catenin, Cell viability assay) are described in the online data supplement at 
http://circres.ahajournals.org. 
Statistical analysis. All data are summarized as mean ± SEM. One-way ANOVA and the 
Fisher’s exact t test were used to compare experimental with control groups. A p value of < 0.05 
was considered statistically significant.  
RESULTS 
IL-1β increases lung vascular permeability via an αvβ6 and TGF-β dependent 
mechanisms. Transient overexpression of IL-1β in lungs of mice by adenoviral gene transfer 
caused an increase in hIL-1β concentrations in BAL fluid at days 4 and 7 after instillation of the 
adenovirus (Figure 1A) that was associated at day 7 with an increased lung endothelial 
permeability to protein (extravascular plasma equivalents, EPE) and the development of 
pulmonary edema (excess lung water, ELW) (Figure 1B&C). Over time, the permeability 
changes decreased and returned back to baseline after 28 days (Figure 1B&C). We found that the 
hIL-1β-mediated increase in lung vascular permeability was associated with a significant increase 
in total cell and neutrophil BAL count with a maximal effect 7 days after Ad-hIL-1β intratracheal 
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instillation (total BAL cell count: Ad-Empty 18 ± 3 vs. Ad-hIL-1β 262 ± 42 cells x 104, p < 0.05; 
BAL neutrophil count: Ad-Empty 5 ± 4% vs. Ad-hIL-1β 86 ± 3%, p < 0.05).  
We have previously found that the increased lung vascular permeability caused by 
lipopolysaccharide (LPS) is TGF-β-dependent and that αvβ6 integrin is critical for the local 
activation of TGF-β.13 Furthermore, the receptors for bacterial products such as Gram-negative-
derived LPS belong to the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) superfamily and 
involved in host defense and inflammation. Thus, we hypothesized that IL-1β may increase lung 
vascular permeability by mechanisms comparable to LPS.14 We treated mice with blocking Ab to 
the αvβ6 integrin and/or soluble chimeric receptor TGF-β type II. Inhibition of the αvβ6 integrin 
and/or TGF-β in the presence of IL-1β significantly reduced the increase in lung vascular protein 
permeability by 50% and the quantity of pulmonary edema by 30%. (Figure 1D&E). When the 
blocking Ab to the αvβ6 integrin and a soluble chimeric receptor TGF-β type II were 
administered together in mice subsequently instilled with Ad-hIL-1β, there was no additional 
inhibition of the IL-1β induced increase in lung vascular permeability (Figure 1D&E). Taken 
together, these results indicate that the adenoviral gene transfer of IL-1β caused an increase in 
lung vascular permeability that is partially mediated by αvβ6 integrin and TGF-β signaling. 
IL-1β increases transepithelial albumin flux in alveolar epithelial type II cells via an 
αvβ6-dependent TGF-β activation. To better understand the mechanism by which IL-1β causes 
the development of protein-rich alveolar edema, we determined whether IL-1β might exert its 
effect on increasing lung epithelial permeability by activating TGF-β via αvβ6 integrin-dependent 
mechanism. IL-1β increased epithelial permeability in polarized rat ATII cells and this effect was 
completely blocked by Ab against the integrin αvβ6 or TGF-β (Figure 2). The next series of 
experiments were designed to determine whether IL-1β would activate TGF-β in rat ATII cells 
and whether other cytokines and chemokines present in the airspace during the early phase of 
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ALI would also activate TGF-β. Rat ATII cells were stimulated with IL-1β, TNF-α, IFN-γ, IL-11, 
CINC-1, KC, MCP-1, MIP-2, MIP-3β or Exodus-2 after being cultured in co-culture system with 
mink lung epithelial reporter cells in order to measure active TGF-β. Among all mediators tested, 
only IL-1β augmented the luciferase activity in these reporter cells, thus indicating activation of 
TGF-β by IL-1β in ATII cells (Figure 3A). TGF-β activation was prevented by blocking the 
αvβ6 integrin or TGF-β, as shown by the luciferase activity in the reporter cells (Figure 3B) or 
by the inhibition of the RhoA-activated kinase (ROCK, immediate downstream effector of RhoA) 
(Figure 3C). Furthermore, Smad2 phosphorylation in ATII cells, a protein that is activated by the 
binding of TGF-β to its receptors and used as a marker of the activation of the TGF-β cell 
signaling was prevented by blocking the αvβ6 integrin or TGF-β (Figure 3D).15 In addition to its 
activation of TGF-β via an αvβ6 integrin-dependent mechanism, IL-1β also increased by 40% the 
expression of TGF-β mRNA measured by RT-PCR in rat ATII cells. Finally, IL-1β activated 
RhoA signaling in rat ATII cells, an effect that was not inhibited by blocking the αvβ6 integrin, 
suggesting that RhoA signaling was upstream of the αvβ6 integrin in the IL-1β signaling leading 
to TGF-β activation (Figure 3E). Alamar Blue assay indicated that none of the mediators at the 
concentrations used in these experiments significantly increased cell death (data not shown). 
Taken together, these data demonstrate that IL-1β increases lung epithelial permeability via an 
RhoA/αvβ6-dependent TGF-β activation and that IL-1β is the only mediator among a series of 
inflammatory mediators important in ALI that activates TGF-β signaling.  
IL-1β increases transendothelial albumin flux in pulmonary artery endothelial cells via 
αvβ5 integrin and RhoA-dependent mechanisms. The results of our in vivo experiments 
indicate that the inhibition of the TGF-β signaling inhibits only 50% of the increase in vascular 
permeability induced by adenoviral IL-1β gene transfer to the lungs. We next determined whether 
IL-1β could directly increase the permeability across bovine pulmonary arterial endothelial cell 
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monolayers (BPAEC). We found that IL-1β induced a dose- and time-dependent increase in 
endothelial permeability, an effect that was completely blocked by its receptor antagonist IL-1RA 
(Figure 4A&B).  
We previously identified the αvβ5 integrin as one of the central regulators of the lung 
endothelial paracellular permeability.16 To determine the role of αvβ5 integrin in mediating IL-1β 
induced increase in lung endothelial permeability, monolayers of BPAEC were pretreated with 
αvβ5-blocking or isotype control Ab and subsequently stimulated with IL-1β. We found that 
blocking the αvβ5 integrin function completely inhibited the IL-1β mediated increased 
permeability across BPAEC monolayers (Figure 5A) and actin polymerization (Figure 5B). 
These in vitro results were confirmed by a last series of in vivo experiments in which mice 
receiving Ad-hIL-1β intratracheally were treated with αvβ5 blocking or isotype control Ab. IL-1β 
mediated increase in vascular permeability was markedly attenuated in mice treated with αvβ5 
blocking Ab (Figure 5C&D). In the next series of experiments, we determined that the 
simultaneous pretreatment with specific antibodies to αvβ5 and αvβ6 integrin provided an 
additive protective effect against the IL-1β-mediated increase in vascular permeability (Figure 
5C&D), demonstrating the critical role of these integrins in mediating the increase in lung 
vascular permeability induced by IL-1β. 
It has previously been reported that the activation of the small GTPase RhoA is important for 
the control of the endothelial barrier function by regulating the actin cytoskeletal organization and 
integrity of intercellular endothelial juntions.17 Thus, we examined whether this small GTPase 
was involved in the cell signaling induced by IL-1β in BPAEC. We found that IL-1β activated 
RhoA within 10 min after stimulation in BPAEC (Figure 6A). Interestingly, this effect was not 
inhibited by blocking the αvβ5 integrin, suggesting that RhoA signaling was upstream of the 
αvβ5 integrin in the IL-1β signaling (Figure 6A). Furthermore, the increase in endothelial 
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albumin flux by IL-1β was completely blocked by the inhibition of the RhoA-activated kinase 
(ROCK, immediate downstream effector of RhoA) (Figure 6B). To further determine the 
mechanisms of IL-1β mediated increase in protein permeability we examined whether exposure 
of BPAEC to IL-1β would affect the actin cytoskeleton. IL-1β stimulation induced the formation 
of actin stress fibers that was blocked by exposing BPAEC to a ROCK inhibitor prior to IL-1β 
stimulation (Figure 6C). Finally, Alamar Blue assay indicated that none of the mediators at the 
concentrations used in these experiments significantly increased cell death (data not shown).  
Previous studies have identified that inflammatory mediators, such as thrombin, VEGF and 
TGF-β, cause myosin phosphorylation, actin polymerization and disruption of the adherens 
junctions by phosphorylation of its components, such as β-catenin, and subsequent degradation 
by the ubiquitin-proteasome system.16, 18 In the present study, we found that IL-1β causes a 
phosphorylation of β-catenin in BPAEC (Figure 7A&C) and that this phosphorylation was 
absent by pretreating the endothelial cells with a ROCK inhibitor or an antibody to the αvβ5 
integrin (Figure 7A&C). Furthermore, IL-1β causes the formation of paracellular gaps between 
lung endothelial cells that was largely prevented by a pretreatment with a ROCK inhibitor or an 
antibody to the αvβ5 integrin (Figure 7B&D). Finally, the formation of paracellular gaps was 
associated with the decrease in the expression of β-catenin at the cell membrane, indicating a 
disassembly of the adherens junction complex (Figure 7B&D). Taken together, these results 
indicate that IL-1β disrupts the adherens junctions and causes the contraction of endothelial cells 
via a RhoA- and αvβ5-dependent mechanisms that lead to increased paracellular permeability. 
DISCUSSION 
Previous clinical studies have reported that IL-1β is one of the most biologically active 
cytokines in the airspace of patients with ALI.3-5 IL-1β has been shown to inhibit fluid transport 
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across the distal lung epithelium,19 to cause surfactant abnormalities20 and to increase protein 
permeability across the alveolar-capillary barrier.21 However, the exact mechanism by which IL-
1β causes an increase in lung epithelial and endothelial permeability is unknown and was 
examined here following the transient overexpression of IL-1β in the lungs by adenoviral gene 
transfer. The effect of IL-1β on lung epithelial and endothelial permeability has been examined in 
previously published studies demonstrating that the increase in permeability across the alveolar-
capillary barrier following the instillation of IL-1α protein into the airspace was blocked by 
pretreatment with TGF-β blocking Ab.22 Furthermore, we recently reported that the increase in 
lung epithelial and endothelial permeability caused by a clinically relevant experimental model of 
ventilator-induced lung injury (VILI) was TGF-β dependent.16 However, these studies did not 
provide any information about a possible causal relationship between IL-1β and TGF-β in 
mediating lung injury caused by VILI. Thus, this is the first study to describe that pretreatment 
with a soluble chimeric TGF-β type II receptor attenuates the increase in lung epithelial and 
endothelial permeability induced by adenoviral gene transfer of IL-1β into the lungs, establishing 
a direct causal relationship between the release of IL-1β within the airspace, the activation of 
TGF-β in the lung, and the increase in epithelial and endothelial permeability induced by IL-1β 
signaling.  
What are the mechanisms of TGF-β activation in the lungs? TGF-β is synthesized as a protein 
complex including the active mature TGF-β (carboxy-terminal fragment) and a disulfide-linked 
homodimer of the amino-terminal fragment (latent associated peptide: LAP).23 This complex is 
further bound to members of another protein family termed TGF-β latent binding proteins. This 
complex is secreted as an inactive complex that is extracellularly cross-linked to fibronectin so 
that latent inactive TGF-β can be stored in large quantity in the extracellular matrix of the lungs.23 
Several mechanisms activate TGF-β outside the cells. First, mild protein denaturation induced by 
  10
changes in temperature or pH, exposure to oxidants or ionizing radiation.24 Second, several 
proteases, such as plasmins, can release free and active TGF-β, although the in vivo importance of 
this activation is unknown. Third, two additional mechanisms of TGF-β activation have probably 
more in vivo relevance: interaction of TGF-β with the secreted protein thrombospondin 1 leading 
to its activation25 and TGF-β activation by the integrin αvβ6 (Figure 8).26 IL-1 receptor type I 
(IL-1RI, the receptor for IL-1β) belongs to the interleukin-1 receptor/Toll-like receptor (IL-
1R/TLR) superfamily that includes the receptors for bacterial products such as Gram-negative 
bacteria-derived endotoxin.14 We have previously shown that exposure to E. coli endotoxin 
caused the in vivo activation of TGF-β that was responsible for the increase in lung epithelial and 
endothelial permeability induced by this bacterial product.13 Thus, we tested whether IL-1β 
would cause an increase in lung permeability across the alveolar-capillary barrier via a αvβ6-
dependent mechanism. We found that inhibition of the αvβ6 integrin by treatment with blocking 
Ab to this integrin significantly decreased the IL-1β induced increase in lung epithelial and 
endothelial permeability. Interestingly, when mice were treated with blocking Ab to the αvβ6 
integrin and a soluble chimeric TGF-β type II receptor, there was no further inhibition of the IL-
1β mediated lung edema, indicating that TGF-β may be activated primarily by the αvβ6 integrin.  
Does IL-1β activate TGF-β via the αvβ6 integrin pathway? It has recently been shown that 
protease-activated receptor 1 (PAR-1) agonists activate TGF-β in an αvβ6 integrin-dependent 
manner via a RhoA-dependent mechanism.15 We determined that IL-1β was the only mediator 
among several, such as TNF-α, IL-8, MIP-1 or MCP-2, that are important in the early phase of 
ALI, to cause the activation TGF-β via RhoA and αvβ6 integrin-dependent mechanisms. It has 
previously been shown that the IL-1 receptor forms a multi-protein complex that can directly 
activate the small GTPase RhoA and causes actin stress fiber formation in epithelial cells.27 Since 
we have previously found that binding to the actin cytoskeleton is required for αvβ6 integrin to 
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allow a change in its conformation that will expose the active form of TGF-β to its receptor,26 it 
explains why the activation of RhoA is necessary for IL-1β to activate the αvβ6 integrin/TGF-β 
pathway. Taken together, these results indicate that IL-1β causes the development of alveolar 
edema via the activation of the RhoA/αvβ6 integrin/TGF-β pathway. 
Our results indicate that the in vivo inhibition of the αvβ6 integrin/TGF-β pathway prevented 
only half of the IL-1β mediated increase in lung epithelial and endothelial permeability. We 
hypothesized that the release of IL-1β within the airspace may also directly cause the 
development of pulmonary edema via binding to its receptors on lung endothelial cells. The IL-1β 
mediated increase in lung endothelial permeability was RhoA-, but not src-dependent (data not 
shown), as we have previously reported for other important mediators of ALI.16 Passage of 
solutes through the endothelial barrier is thought to occur via transcellular pathway or through 
receptor-activated transcytosis.28 The relative contribution of these pathways remains 
incompletely understood. However, it has been suggested that the formation of actin stress fibers 
and of gaps between cells as the consequence of imbalanced competition between cytoskeletal, 
adhesive cell-cell and cell-matrix forces leads to an increased flux of solutes and protein via the 
paracellular pathway.28 In our experimental model, IL-1β induced the formation of actin stress 
fibers and paracellular gaps and caused the disassembly the adherens junction complex. In 
addition, these results were confirmed by the next series of experiments that showed a critical 
role for the αvβ5 integrin in controlling the increase in lung endothelial permeability as well as 
the formation of actin stress fibers mediated by IL-1β. Although our studies did not directly 
distinguish between paracellular and transcellular pathways, these results suggest that the 
paracellular pathway plays a role in the IL-1β-mediated increase in lung epithelial and endothelial 
permeability.  
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A limitation of this series of studies is that we used cells from various species as well as cells 
derived from proximal pulmonary macrovascular endothelium. Indeed, microvascular lung 
endothelial cells would be more relevant to study pulmonary capillary leak, as several studies 
have shown significant physiologic differences between lung cells from microvascular and 
macrovascular beds.29, 30 In order to address this question, we performed additional series of in 
vivo experiments in mice by blocking either the αvβ5 or both the αvβ5 and αvβ6 integrins. The 
results showed that the IL-1β mediated development of pulmonary edema was attenuated in mice 
treated with a blocking Ab to the αvβ5 integrin and further reduced in mice treated with blocking 
Abs to both the αvβ5 and αvβ6 integrins. Thus, taken together, these results demonstrate the 
consistency of the IL-1β signaling pathway across species and support a critical role for both 
integrins in mediating the increase in lung endothelial paracellular permeability induced by 
exposure to IL-1β. 
In summary, these studies demonstrate for the first time a critical and sequential role for the 
αvβ5/β6 integrins in mediating development of alveolar edema caused by IL-1β, one of the most 
biologically important inflammatory mediators in the airspace of patients with early ALI.3-5 We 
specifically found that the inhibition of αvβ6 integrin/TGF-β signaling completely blocked the 
IL-1β mediated protein permeability across the distal lung epithelium and prevented in large part 
the development of pulmonary edema following transient overexpression of IL-1β in the lungs by 
adenoviral gene transfer. Furthermore, IL-1β increased the protein permeability across lung 
endothelial cell monolayers via RhoA- and αvβ5 integrin-dependent mechanisms. Finally, the 
combined inhibition of the αvβ5 and αvβ6 integrins considerably reduced the lung injury 
associated with the adenoviral gene transfer of IL-1β into the lungs. The findings reported here 
have potential clinical relevance. Indeed transient blockade of both integrins by humanized Ab or 
small RGD peptides may provide new causal therapies for pulmonary edema from ALI, a 
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substantial cause of morbidity and mortality in critically ill patients that is currently largely 
untreatable.  
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FIGURE LEGENDS 
Figure 1. IL-1β increases mouse lung vascular permeability that is partially mediated 
via αvβ6 integrin- and TGF-β-dependent mechanisms. Panel A. Levels of human IL-1β (hIL-
1β) were measured in bronchoalveolar lavage (BAL) fluid by ELISA. Panels B&C. Extravascular 
plasma equivalents (EPE, µl) and excess lung water (ELW, µl) were measured in mouse lung 
after recombinant adenovirus (2.5 x 108 PFU) expressing human IL-1β (Ad-hIL-1β), control 
adenovirus or PBS was instilled intratracheally into wild-type mice (C57BL/6J). Panels D&E. 
Recombinant adenovirus (2.5 x 108 PFU) expressing human IL-1β (Ad-hIL-1β), control 
adenovirus or PBS was instilled intratracheally into wild-type mice. Mice were sacrificed at day 
7. Some of the wild-type mice were treated with blocking or control Ab for αvβ6 integrin (1 
mg/kg i.p. at day 3) and/or soluble chimeric TGF-β type II receptor or vehicle (sTGFβII Rec; 2 
mg/kg i.p. at day 0, 3 and 5). For all experiments, data are shown as mean ± SEM, n = 8/group, * 
p < 0.05 compared with control mice (Ad-Empty, Panels A-C), or with Ad-hIL-1β and control Ab 
or vehicle (Panels D-E). 
Figure 2. IL-1β increases protein permeability across rat ATII cell monolayers via αvβ6 
integrin or TGF-β-dependent mechanisms. Rat ATII cell monolayers were exposed to IL-1β 
(10ng/ml) or its vehicle for 4 h. Some cell monolayers were pretreated with blocking Ab to the 
integrin αvβ6 (30 μg/ml) and TGF-β (10 μg/ml) or their respective control isotype Ab. 
Paracellular protein permeability was measured with 125I-albumin. Data are shown as mean ± 
SEM. * p ≤ 0.05 from controls. 
Figure 3. IL-1β activates TGF-β signaling via a RhoA/αvβ6 integrin-dependent 
mechanism in rat ATII cell monolayers. Panel A. Rat ATII cell monolayers were stimulated 
with one of the following cytokines/chemokines: IL-1β (10 ng/ml), TNF-α (10 ng/ml) , IFN-γ (10 
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ng/ml), IL-11 (25 ng/ml), CINC-1 (100 ng/ml), KC (500 ng/ml), MCP-1 (100 ng/ml), MIP-2 (100 
ng/ml), MIP-3β (250 ng/ml) and Exodus-2 (100 ng/ml) prior to being co-cultured with mink lung 
epithelial reporter cells, as described in methods.  Cell lysates were assayed for luciferase activity. 
Panel B. Rat ATII cell monolayers were stimulated with IL-1β (10 ng/ml) for 24 h and TGF-β 
activation was measured by co-culture with mink lung epithelial cells as described in methods. 
Panel C. Rat ATII cell monolayers were exposed to IL-1β (10ng/ml) or its vehicle for 4 h. Some 
cell monolayers were pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) or its vehicle 
before exposure to IL-1β or its vehicle. Active TGF- β was detected using ELISA. Panel D. Rat 
ATII cell monolayers were stimulated with IL-1β for 30 min, cells were lysed and phospho- and 
total Smad2 were detected by Western blotting. Some cell monolayers were pretreated with 
blocking Ab to the integrin αvβ6 (30 μg/ml) and TGF-β (10 μg/ml) or their respective control 
isotype Ab. Panel E. Rat ATII cell monolayers were treated with IL-1β (10 ng/ml) or its vehicle 
for 10 min. Some cell monolayers were pretreated with blocking Ab to the integrin αvβ6 (30 
μg/ml) or its respective control isotype Ab. RhoA activity was measured as described in Methods. 
All experiments were performed at least in triplicates and repeated three times. Data are shown as 
mean ± SEM. * p ≤ 0.05 from controls. 
Figure 4. IL-1β increases protein permeability across bovine pulmonary arterial 
endothelial cell monolayers (BPAEC). Panel A. BPAEC cell monolayers were treated with IL-
1β (3-50 ng/ml) or its vehicle for 1 h. Some cell monolayers were pretreated with IL1RA (10 
μg/ml) or its vehicle before exposure to IL-1β or its vehicle. Paracellular protein permeability 
was measured with 125I-albumin. Panel B. BPAEC were treated with IL-1β (10 ng/ml) or its 
vehicle for 1-12 h. Paracellular protein permeability was measured with 125I-albumin. Data are 
shown as percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from controls. 
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Figure 5. IL-1β-mediated increase in lung endothelial permeability is αvβ5 integrin-
dependent. Panel A. BPAEC cell monolayers were treated with IL-1β (10 ng/ml) or its vehicle 
for 1 h. Some cell monolayers were pretreated with blocking Ab to the αvβ5 integrin or isotype 
control Ab before exposure to IL-1β or its vehicle. Paracellular protein permeability was 
measured with 125I-albumin. Data are shown as percent of controls; results are shown as means ± 
SEM; * p ≤ 0.05 from controls; ** p ≤ 0.05 from cell monolayers treated with IL-1β alone. Panel 
B. BPAEC cell monolayers were treated with IL-1β (10 ng/ml) or its vehicle for 10 min. Cell 
monolayers were either pretreated with blocking Ab to αvβ5 integrin or isotype control Ab before 
exposure to IL-1β or its vehicle. Cells were then fixed, permeabilized and incubated with 
rhodamin-phalloidin. Panels C&D. Recombinant adenovirus (2.5 x 108 PFU) expressing human 
IL-1β (Ad-hIL-1β) or control adenovirus was instilled intratracheally into wildtype mice 
(C57BL/6J). The animals were sacrificed at day 7 and the extravascular plasma equivalents (EPE, 
µl) and excess lung water (ELW, µl) were measured as described in Methods. Mice were also 
treated with either a specific blocking Ab to αvβ5 integrin, or specific blocking Abs to αvβ5 and 
αvβ6 integrins or their isotype control Abs (1 mg/kg i.p. at days 1, 3 and 5 after intratracheal 
instillation of adenoviruses). Data are shown as mean ± SEM, n = 8/group, * p < 0.05 compared 
with mice treated with Ad-hIL-1β and control Ab; ** p < 0.05 compared with mice treated with 
Ad-hIL-1β and blocking Ab to αvβ5 integrin. 
Figure 6. IL-1β-mediated increase in protein permeability across bovine pulmonary 
arterial endothelial cell monolayers is RhoA-dependent. Panel A. BPAEC cell monolayers 
were treated with IL-1β (10 ng/ml) or its vehicle for 10 min. Some cell monolayers were 
pretreated with blocking Ab to the αvβ5 integrin or isotype control Ab before exposure to IL-1β 
or its vehicle. RhoA activity was measured as described in Methods. Data are shown as percent of 
controls; results are shown as means ± SEM; * p ≤ 0.05 from controls. Panel B. BPAEC cell 
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monolayers were treated with IL-1β (10 ng/ml) or its vehicle for 1 h. Some cell monolayers were 
pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) or its vehicle before exposure to IL-
1β or its vehicle. Paracellular protein permeability was measured with 125I-albumin. Data are 
shown as percent of controls; results are shown as means ± SEM; * p ≤ 0.05 from controls; ** p ≤ 
0.05 from cell monolayers treated with IL-1β alone. Panel C. BPAEC cell monolayers were 
treated with IL-1β (10 ng/ml) or its vehicle for 10 min. Some cell monolayers were pretreated 
with a RhoA kinase inhibitor (Y-27632) (10 μM) or its vehicle before exposure to IL-1β or its 
vehicle. Cells were then fixed, permeabilized and stained with rhodamin-phalloidin and Ab to the 
αvβ5 integrin or isotype control Ab.  
Figure 7. IL-1β causes adherens junction disassembly and formation of paracellular 
gaps in bovine pulmonary arterial endothelial cell monolayers. Panel A. BPAEC cell 
monolayers were treated with IL-1β (10 ng/ml) or its vehicle for 10 min. Some cell monolayers 
were pretreated with blocking Ab to the αvβ5 integrin or isotype control Ab before exposure to 
IL-1β or its vehicle. Cell lysates were subjected to immunoprecipitation with an Ab against β-
catenin and immunoblotted with an Ab to phosphotyrosine. The same blots were then reprobed 
with an Ab to β-catenin. Panel B. BPAEC cell monolayers were treated with IL-1β (10 ng/ml) or 
its vehicle for 4 h. Some cell monolayers were pretreated with blocking Ab to the αvβ5 integrin 
or isotype control Ab before exposure to IL-1β or its vehicle. Cells were then fixed, 
permeabilized and incubated with a primary Ab against β-catenin and a FITC-conjugated 
secondary antibody. Panel C. BPAEC cell monolayers were treated with IL-1β (10 ng/ml) or its 
vehicle for 10 min. Some cell monolayers were pretreated with a RhoA kinase inhibitor (Y-
27632) (10 μM) or its vehicle before exposure to IL-1β or its vehicle. Cell lysates were subjected 
to immunoprecipitation with an Ab against β-catenin and immunoblotted with an Ab to 
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phosphotyrosine. The same blots were then reprobed with an Ab to β-catenin. Panel D. BPAEC 
cell monolayers were treated with IL-1β (10 ng/ml) or its vehicle for 4 h. Some cell monolayers 
were pretreated with a RhoA kinase inhibitor (Y-27632) (10 μM) or its vehicle before exposure 
to IL-1β or its vehicle. Cells were then fixed, permeabilized and incubated with a primary Ab 
against β-catenin and a FITC-conjugated secondary antibody.  
Figure 8. Schematics of the effect IL-1β on the alveolar capillary barrier. Our model 
diagrams the IL-1β signaling pathway that leads to an increase in lung epithelial and endothelial 
permeability. IL-1β causes an increase in RhoA activity (a), leading to TGF-β activation via the 
αvβ6 integrin (b) (reference 26). TGF-β induces an increase in permeability (c) (reference 13), 
and an inhibition of the Na+-driven fluid transport (d) in alveolar epithelial cells (reference 12). 
Subsequent binding of TGF-β on its receptor on endothelial cells induces an increase in lung 
endothelial permeability via a RhoA-dependent phosphorylation of the VE-cadherin (f) (reference 
31), and a formation of actin stress fibers (i). We further show that IL-1β activates RhoA (g) and 
increases lung endothelial permeability via the phosphorylation and endocytosis of β-catenin (h) 
and αvβ5 integrin–dependent stress fibers formation in lung endothelial cells (i). 
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MATERIALS AND METHODS, Online Data Supplement 
Reagents and antibodies. All cell culture media were prepared by the University of California 
San Francisco Cell Culture Facility using deionized water and analytical grade reagents. Human 
recombinant IL-1β and IL-1β receptor antagonist (IL-1RA) were obtained from R&D Systems 
(Minneapolis, MN). Bovine recombinant IL-1β was obtained from Pierce (Rockford, IL). 
Blocking studies were performed with anti-αvβ6 blocking (3G9) and type specific control 
antibodies (Ab) (generous gift from Gerald Horan, Biogen Idec, Cambridge, MA1), mouse 
monoclonal blocking Ab against all isoforms of TGF-β (1D11; R&D Systems, Minneapolis, MN) 
or soluble chimeric TGF-β type II receptor (sTGFβRII, generous gift from Gerald Horan, Biogen 
Idec, Cambridge, MA), RhoA kinase (ROCK) inhibitor (Y-27632; Calbiochem, San Diego, CA) 
and mouse anti-mouse αvβ5 blocking Ab (ALULA) and its type specific control Ab (generous 
gift from Dean Sheppard, University of California San Francisco, CA2). Rabbit polyclonal anti–
phospho and anti–total Smad2 was obtained from Cell Signaling Technology (Danvers, MA), β-
catenin antibody was purchased for Santa Cruz Biotechnologies (Santa Cruz, CA). Lysis buffer 
(5x) concentrates and luciferase substrates were purchased from Promega (Madison, WI). The 
protein concentration of cell lysates was determined using a Bio-Rad protein assay kit or a BCA 
kit (Pierce, Rockford, IL). The chemiluminescence ECL Plus kit was obtained from Amersham 
Biosciences. 125I-labeled human serum albumin was used as radioactive tracer (Jeanatope ISO-
TEX Diagnostics, Friendswood, TX). 
Recombinant Adenovirus. The recombinant adenovirus expressing human IL-1β (Ad-hIL-1β) 
was a generous gift from Dr. Jack Gauldie (McMaster University, Hamilton, Ontario, Canada) 
and has been described in detail elsewhere.3 Briefly, the human IL-1β cDNA has been cloned into 
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a p73 shuttle vector with a human CMV promoter and co-transfected with a plasmid containing 
E1-E3 deleted type 5 adenoviral genome. The donated replication-deficient virus was then 
commercially amplified and purified by cesium chloride gradient centrifugation and PD-10 
Sephadex chromatography, plaque tittered on 293 cells and checked for wild-type contamination 
(ViraQuest Inc., North Liberty, IA). The control vectors, Ad-Empty, had no heterologous gene 
recombined in the deleted E1-E3 region. 
Animal studies 
Animals. The Committee for Animal Research (University of California, San Francisco, CA) 
reviewed and approved the study. Male, 7 week old wildtype mice (C57BL/6J) were purchased 
from The Jackson Laboratory. The animals were housed in air-filtered, temperature-controlled 
units (20±2°C) with food and water ad libitum.  
Experimental protocol. Mice were anesthetized with an intraperitoneal (i.p.) injection of a 
mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg). Then, Ad-hIL-1β or Ad-Empty (2.5 x 
108 PFU in 75 µl sterile PBS) was instilled intratracheally with a microsprayer (IA-1C 
MicroSprayer™, PennCentury, Philadelphia, PA) using the direct visualized instillation (DVI) 
technique.3 Mice were closely followed and sacrificed at day 4, 7, 14, and 28 after adenoviral 
administration. Because we found that the maximal increase in lung endothelial permeability and 
pulmonary edema was seen at day 7 after Ad-ILβ administration, blocking studies were done in 
another group of animals after 7 days of adenoviral gene transfer. Some animals were 
additionally treated either with a blocking Ab to αvβ5 integrin (4 mg/kg i.p. at days 1, 3, 5), or 
with a blocking Ab to αvβ6 integrin (1 mg/kg i.p. at days 1, 3, 5) or treated with both αvβ5 and 
αvβ6 integrin blocking antibodies, or with their respective control Abs. Additional mice were 
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treated with soluble chimeric TGF-β type II receptor or vehicle (sTGFβII Rec; 2 mg/kg i.p. at 
days 0, 3 and 5). 
Measurement of lung endothelial permeability to protein and pulmonary edema. 
Extravascular plasma equivalents (EPE, µl) and excess lung water (ELW, µl) were measured to 
determine the lung endothelial permeability to protein and pulmonary edema. We have described 
this technique previously in detail.4 Briefly, 0.5 µCI of 125I-albumin was injected i.p. 4 h before 
sacrificing the animals to ensure adequate tracer distribution. The blood was collected through 
puncture of the inferior vena cava. Then, the lungs were removed, counted in a Wizard γ-counter 
(Perkin-Elmer, Waltham, MA), weighted, and homogenized. The homogenate was weighted and 
a fraction centrifuged (12,000 x g, 8 min) for assay of hemoglobin concentration in the 
supernatant. Another fraction of homogenate, supernatant and blood were weighted and then 
dried in an oven (60°C for 48h) for gravimetric determination of the extravascular lung water. 
The lung wet-to-dry weight ratio (lung W/D ratio) was determined by standard formula and ELW 
calculated: 
ELW  =  (lung W/D ratioexperimental x lung dry weightexperimental 
 – lung W/D rationormal x lung dry weightnormal) x 1000 (µl) 
EPE were calculated as the counts of 125I-albumin in the blood free lung tissue divided by the 
counts of 125I-albumin in the plasma.  
Bronchoalveolar lavage (BAL) fluid and cell count. We used the methods that we previously 
described.5 The white blood cells were counted by an automated counter (Beckman Coulter, Inc. 
Fullerton, CA). Blood cell smear was made using cytospin (Shandon Inc, Pittsburgh, PA). The 
slides were visualized using Wright-Giemsa staining (Fisher Scientific Co., Middletown, VA).  
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Measurement of IL-1β. The levels of human IL-1β in BAL were measured by a 
commercially available ELISA (R&D Systems Inc, Minneapolis, MN) according to the 
manufacturer’s protocol. 
In vitro studies 
Cell culture. All cells were kept in Dulbecco's modified Eagle's medium/H21 medium 
containing 10% low endotoxin FBS and 1% penicillin/streptomycin/amphotericin in a humidified 
95% air and 5% CO2 environment at 37°C. Primary rat alveolar epithelial type II (ATII) cells 
were isolated as we have described previously6 and cultured on 6.5 mm polycarbonate Transwell 
dishes (0.4 µm pore size; Corning Life Sciences). 24 h later, non-adherent epithelial cells were 
removed by washing with PBS, and the cells transitioned to an air-liquid interface by adding 
fresh medium to the lower compartments of the Transwell dishes. Mink lung epithelial cells 
stably transfected with a luciferase reporter plasmid under the control of the plasminogen 
activator inhibitor-1 promoter (TMLC cells7) were obtained from Daniel Rifkin (New York 
University, New York, NY) and used in co-culture with ATII cells to measure TGF-β activation 
as we have previously published.4 Bovine pulmonary arterial endothelial cells (BPAEC; ATCC, 
CCL-209; passages all < 8) were used for lung endothelial studies.2  
Measurement of transepithelial and transendothelial albumin fluxes. To study the 
transepithelial albumin flux, ATII cells were plated and cultured on polycarbonate Transwells as 
described above. After 72–96 h, cells that formed confluent monolayers reaching a transepithelial 
electrical resistance (TER) >1500 ohms/cm2 were used for experimentation as we have described 
previously.4 Anti-αvβ6 (30 μg/ml), anti-TGF-β (10 μg/ml) blocking Ab or their isotype control 
Ab were added to the basolateral compartment of some transwells for 30 min and then stimulated 
with IL-1β (10 ng/ml) for 4 h. Transepithelial albumin flux across each monolayer was 
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determined by the addition of 0.05 μCi 125I-labeled human serum albumin to each upper 
compartment for 1 h at 37°C, after which contents from the lower compartment were collected 
and counted in a Wizard γ-counter (Perkin-Elmer, Waltham, MA). Only monolayers retaining ≥ 
97% of tracer at baseline were studied. We measured the transendothelial albumin flux, as we 
have done before.2 Briefly, cells were seeded onto 6.5 mm collagen coated PFTE membrane 
Costar Transwells (Fisher Scientific) at 1 x 105 cells per well and cultured to confluence. Cells 
were stimulated with IL-1β (0-50 ng/ml) for 1-12 h. In some experiments, cells were pre-treated 
with Y-27632 / vehicle (10 μM) or anti-αvβ5 blocking / type specific control Ab (25 μg/ml) for 
30 min. For the last hour of incubation, 125I-albumin (0.05 µCi) was applied to each upper 
compartment at 37°C, after which contents from the lower compartment were collected and 
counted in the Wizard γ-counter. Only monolayers retaining > 90% of tracer at baseline were 
studied. 
Bioassay for TGF-β activation. Polarized rat ATII cells (5 x 105 cells) were stimulated on the 
basolateral side with IL-1β (10 ng/ml) and a series of other cyto- or chemokines, i.e., TNF-α (10 
ng/ml) , IFN-γ (10 ng/ml), IL-11 (25 ng/ml), CINC-1 (100 ng/ml), KC (500 ng/ml), MCP-1 (100 
ng/ml), MIP-2 (100 ng/ml), MIP-3β (250 ng/ml) and Exodus-2 (100 ng/ml). Anti-αvβ6 (30 
μg/ml), anti-TGFβ (10 μg/ml) blocking Ab or their isotype control Ab were added to the 
basolateral compartment of some Transwells for 30 min before stimulation. Then, as we have 
described previously,4 mink lung epithelial reporter cells (TMLC; 5 x 104 cells), expressing 
firefly luciferase under the control of the TGF-β sensitive plasminogen activator inhibitor-1 
promoter, were seeded onto the ATII cell monolayer in absence or presence of blocking Ab. Co-
culture was maintained for 16–20 h, and the final lysates were assayed for luciferase activity, as 
previously described.4 
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Measurement of active TGF-β. Rat active TGF-β1 levels were measured in triplicate by a 
commercially available enzyme-linked immunosorbent assay (ELISA; from R&D Systems 
(Minneapolis, MN). The assays were performed according to the manufacturer’s protocol; on 
primary rat alveolar type II cells. The sensitivity of the assay was 1.7 pg/mL active TGF-β1. This 
assay recognizes both natural and recombinant TGF-β1. No significant cross-reactivity or 
interference was observed. 
Quantitative real-time RT-PCR. Total RNA was extracted from rat or human ATII cells 
cultured for 4 days at air-liquid interface, using the RNeasy Mini kit (Qiagen, Valencia, CA). 1 
μg of total RNA was reverse transcribed using the Superscript first-strand synthesis system 
(Invitrogen, Carlsbad, CA). The RT-PCR reactions were performed and analyzed using the ABI 
PRISM 7700 Sequence Detection system (PE-ABI). Briefly, the RT-PCR reaction was carried 
out in a 25-µl reaction mixture containing 1 x TaqMan Universal PCR Master Mix (PE-
Biosystems, Foster City, CA), 10 pmol primers, 5 pmol TaqMan probe and an equivalent of 100 
ng of total RNA, for 40 cycles at 95°C for 15 s and 60°C for 1 min. The number of cycles to 
threshold (CT) of fluorescence detection was normalized to the CT of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) for each sample tested. Results are expressed as a 
percentage in complementary DNA abundance compared to control. The percentages values were 
used for all statistical comparisons. Rat TGF-β1 primer set: Forward: 
GCTGCTGACCCCCACTGAT, Reverse: GCCACTGCCGGACAACTC, Probe: 
CGCCTGAGTGGCTGTCTTTTGACGTC. Rat GAPDH primer set: Forward: 
CTGCCAAGTATGATGACATCAAGAA, Reverse: AGCCCAGGATGCCCTTTAGT, Probe: 
TCGGCCGCCTGCTTCACCA. 
RhoA activation assay. RhoA activity was determined from endothelial and alveolar 
epithelial cells using the luminescence-based G-LISATM RhoA activation assay biochemistry kit 
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according to the manufacturer's instructions (Cytoskeleton Inc., Denver, CO). Briefly, after serum 
starvation, cells were stimulated with IL-1β (10 ng/ml) for 10 min and lysed. The lysates were 
clarified by centrifugation at 4°C (8,000 x g, 2 min), the protein concentration determined, and 
the final protein concentrations adjusted to 1.0 mg/ml. After incubating the lysates in the Rho-
GTP affinity plate and adding the secondary Ab and detection reagents, luminescence was 
determined using the Wallac Victor 1420 (Perkin Elmer, Shelton, CT). 
Western blot analysis for detecting phospho-Smad2. Western blot analysis was performed, 
as previously described.6 After equal amounts of protein were loaded in each lane and separated 
by 10% SDS-PAGE, proteins were transferred to Immobilon-P membranes (Millipore, Bedford, 
MA). Membranes were blocked with 5% dry milk in PBS containing 0.1% Tween-20 and 
incubated with the primary Ab (1:1,000) overnight at 4°C and with horseradish peroxidase-
conjugated secondary Ab (1:2,000) for 1 h at room temperature. Proteins were visualized using 
chemiluminescence.  
Immunofluorescence for visualization of β-catenin and actin stress fibers. Endothelial cells 
were grown on collagen coated glass coverslips to confluence. Cells were serum starved for 6 h 
and pre-treated with either Y-27362 (10 μM), anti- β-catenin Ab (10 μg/ml), control Ab (10 
μg/ml) or vehicle (normal saline) for 1 h, then stimulated with IL-1β (10 ng/ml) for 10 min (actin 
stress fibers staining) or 4 h (β-catenin staining). Cells were then fixed with 4% 
paraformaldehyde for 20 min, permeabilized with 0.3% Triton X-100, then stained with Texas 
Red-X phalloidin (Invitrogen Life Technologies) for actin stress fibers. For β-catenin staining, 
cells were incubated with primary antibody for β-catenin or αvβ5 integrin for 2 hours (1:50 
dilution) at room temperature, then cells were incubated with FITC conjugated antibody for 1 
hour (1:50 dilution) at room temperature, mounted, and imaged using a Leica DM5000B 
microscope equipped for epifluorescence.  
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Immunoprecipitation for detecting phospho-β-catenin. Endothelial cells were grown on 
collagen coated 35 mm cell culture plates to confluence. Cells were pretreated with either Y-
27362 (10 μM), anti-αvβ5 blocking Ab (10 μg/ml), control Ab (10 μg/ml) or vehicle (normal 
saline) for 1 h, then stimulated with IL-1β (10 ng/ml) for 10 min. Cells were then washed twice in 
PBS, and solubilized in lysis buffer (150 mM NaCl, 5 mM MgCl2, 10 mM Tris HCl, pH 7.5 
[TBS], 1% Triton X-100), supplemented with a cocktail of phophatase and protease inhibitors. 
The lysates were pre-cleared with protein G-Sepharose beads, and incubated with 2 μg of a rabbit 
polyclonal Ab to β-catenin (Santa Cruz Biotechnology) overnight at 4°C. Then, the cell lysate 
was incubated with protein G-Sepharose beads under continuous mixing for 2 h at 4°C. The 
Sepharose bound immune complexes were washed with lysis buffer and boiled in 2x Laemmli 
sample buffer. The proteins were separated by 7.5% SDS-PAGE, transferred onto nitrocellulose 
membranes, blocked with 5% milk in TBS containing 0.1% Tween-20, and incubated with the 
appropriate Ab (1:1,000 dilution of rabbit polyclonal Ab to phosphotyrosine (Upstate 
Biotechnology) overnight at 4°C; 1:2,000 dilution of goat anti-rabbit IgG conjugated with 
peroxidase (MP biomedicals) for 1 h at room temperature). Immunoreactive bands were 
visualized using enhanced chemiluminescence. 
Cell Viability. Cell viability after exposure to the different experimental conditions was 
measured by the Alamar Blue assay.8 Cell media were replaced with media containing 10% 
Alamar Blue and the cells placed back in the cell incubator for 2 h. The media were collected and 
read on a plate reader at 530 nm. 
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